Zhida is a specialty pharma company focusing on the innovation in drug delivery systems, the technology and industrialization of nano-drug delivery platforms. The company owns multiple patents with core technologies, including nanoliposome drug delivery platform, albumin nanoparticle drug delivery platform, etc. There is a small-volume injection production line specifically designed for nano liposome injection product which has passed the GMP compliance inspection.

　　The company has successfully developed the first generic drug of nanoliposome - doxorubicin liposomal injection (Zhisai), which has been approved by the NMPA and is considered to be bioequivalent to the reference drug.

　　Zhida will continue to cultivate deeply in R&D and commercialization of drugs based on the new drug delivery system (NDDS), serve the patients with more accurate and effective treatment options.Go China GO ！